Drs. Swami and Ciuro discuss real-world data that indicates a shift in mHSPC treated with intensified therapy since 2023.
mHSPC/mCSPC
Advertisement
Dr. Shore highlights post hoc analyses of ultra-low PSA responses and their correlation with outcomes in the ARANOTE study.
A recent study evaluated the impact of early withdrawal of upfront ARSIs on clinical outcomes in patients with mCSPC.
Patients with ARPI-treated mCSPC and BRCA1/2 alterations experienced higher rates of disease progression.
Apalutamide can boost rPFS and OS in patients with mHSPC when diagnosed via conventional imaging.
Dr. Antonarakis discusses the differences between PARP1 mRNA expression and other biomarkers used for risk stratification.
Dr. Morris discusses trials and rationale behind using PSMA therapy earlier in prostate cancer treatment.
Dr. Ciuro discusses key factors to consider when choosing between doublet and triplet therapy for mHSPC.
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
Roundtable Discussions
The panel explores the the role of imaging, genomics, and patient factors in the management of mHSPC.
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
Prostate Cancer Knowledge Hubs
Advertisement
Section Editor
Jordan Ciuro, MDAssistant Professor of Medicine & Medical Oncologist | Emory Winship Cancer Institute
Advertisement
Get the latest mHSPC research straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.